These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 22380774)

  • 21. Cystobactamids: myxobacterial topoisomerase inhibitors exhibiting potent antibacterial activity.
    Baumann S; Herrmann J; Raju R; Steinmetz H; Mohr KI; Hüttel S; Harmrolfs K; Stadler M; Müller R
    Angew Chem Int Ed Engl; 2014 Dec; 53(52):14605-9. PubMed ID: 25510965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.
    Kashyap M; Kandekar S; Baviskar AT; Das D; Preet R; Mohapatra P; Satapathy SR; Siddharth S; Guchhait SK; Kundu CN; Banerjee UC
    Bioorg Med Chem Lett; 2013 Feb; 23(4):934-8. PubMed ID: 23321564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dihydroxylated 2,4,6-triphenyl pyridines: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
    Karki R; Thapa P; Yoo HY; Kadayat TM; Park PH; Na Y; Lee E; Jeon KH; Cho WJ; Choi H; Kwon Y; Lee ES
    Eur J Med Chem; 2012 Mar; 49():219-28. PubMed ID: 22318164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity.
    Abdel-Aziz M; Park SE; Abuo-Rahma Gel-D; Sayed MA; Kwon Y
    Eur J Med Chem; 2013 Nov; 69():427-38. PubMed ID: 24090914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gossypol interferes with both type I and type II topoisomerase activities without generating strand breaks.
    Senarisoy M; Canturk P; Zencir S; Baran Y; Topcu Z
    Cell Biochem Biophys; 2013 May; 66(1):199-204. PubMed ID: 23161103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
    Tse-Dinh YC
    Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poison.
    Godbole AA; Ahmed W; Bhat RS; Bradley EK; Ekins S; Nagaraja V
    Biochem Biophys Res Commun; 2014 Apr; 446(4):916-20. PubMed ID: 24642256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
    Mitton-Fry MJ; Brickner SJ; Hamel JC; Barham R; Brennan L; Casavant JM; Ding X; Finegan S; Hardink J; Hoang T; Huband MD; Maloney M; Marfat A; McCurdy SP; McLeod D; Subramanyam C; Plotkin M; Reilly U; Schafer J; Stone GG; Uccello DP; Wisialowski T; Yoon K; Zaniewski R; Zook C
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3353-3358. PubMed ID: 28610977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Towards anticancer fluoroquinolones: A review article.
    Abdel-Aal MAA; Abdel-Aziz SA; Shaykoon MSA; Abuo-Rahma GEA
    Arch Pharm (Weinheim); 2019 Jul; 352(7):e1800376. PubMed ID: 31215674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of novel bacterial topoisomerase I inhibitors by use of in silico docking and in vitro assays.
    Sandhaus S; Chapagain PP; Tse-Dinh YC
    Sci Rep; 2018 Jan; 8(1):1437. PubMed ID: 29362471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
    Pan X; Hartley JM; Hartley JA; White KN; Wang Z; Bligh SW
    Phytomedicine; 2012 May; 19(7):618-24. PubMed ID: 22402246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics.
    Tse-Dinh YC
    Future Med Chem; 2015; 7(4):459-71. PubMed ID: 25875873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic.
    Holden JA
    Curr Med Chem Anticancer Agents; 2001 May; 1(1):1-25. PubMed ID: 12678768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gold(III) complexes of pyridyl- and isoquinolylamido ligands: structural, spectroscopic, and biological studies of a new class of dual topoisomerase I and II inhibitors.
    Wilson CR; Fagenson AM; Ruangpradit W; Muller MT; Munro OQ
    Inorg Chem; 2013 Jul; 52(14):7889-906. PubMed ID: 23815163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
    Chen W; Qiu J; Shen YM
    Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and structure-activity relationship studies of 4-arylthiosemicarbazides as topoisomerase IV inhibitors with Gram-positive antibacterial activity. Search for molecular basis of antibacterial activity of thiosemicarbazides.
    Siwek A; Stączek P; Stefańska J
    Eur J Med Chem; 2011 Nov; 46(11):5717-26. PubMed ID: 21978836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advancements in the medicinal chemistry of bacterial type II topoisomerase inhibitors.
    Jaswal S; Nehra B; Kumar S; Monga V
    Bioorg Chem; 2020 Nov; 104():104266. PubMed ID: 33142421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs acting on DNA topoisomerases: recent advances and future perspectives.
    Gatto B; Capranico G; Palumbo M
    Curr Pharm Des; 1999 Mar; 5(3):195-215. PubMed ID: 10066890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV.
    Kokot M; Anderluh M; Hrast M; Minovski N
    J Med Chem; 2022 May; 65(9):6431-6440. PubMed ID: 35503563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. l,8-Naphthalimide based DNA intercalators and anticancer agents. A systematic review from 2007 to 2017.
    Tomczyk MD; Walczak KZ
    Eur J Med Chem; 2018 Nov; 159():393-422. PubMed ID: 30312931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.